60 Degrees Pharmaceuticals Begins Enrolling For A Clinical Trial Of Tafenoquine For Babesiosis At Tufts Medical Center
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharmaceuticals has partnered with Tufts Medical Center to conduct the first clinical trial evaluating tafenoquine for treating babesiosis in humans. Enrollment will start on June 13, 2024, in Boston, with plans to expand recruitment to other hospitals in the Northeast U.S.
May 30, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct the first clinical trial of tafenoquine for babesiosis. This partnership could potentially lead to a new treatment for the orphan disease, which may positively impact the company's stock.
The partnership with Tufts Medical Center to conduct a groundbreaking clinical trial for tafenoquine in treating babesiosis is a significant development for 60 Degrees Pharmaceuticals. If the trial shows positive results, it could lead to a new treatment for an orphan disease, potentially boosting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100